Legal status · United States
Is FGF21 legal in the United States?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. FGF21 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
FGF21 in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| Note | Native FGF21 is not a product. The analogues efruxifermin, pegozafermin and efimosfermin are investigational. |
| FDA approval status | Not FDA-approved. Native FGF21 is not a drug. No FGF21 analogue (efruxifermin, pegozafermin, efimosfermin) had a Drugs@FDA record on 11 September 2026; efruxifermin and pegozafermin are in phase 3. |
| Human studies cited | 4 of 10 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the FGF21 profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
FGF21 is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What FGF21 is
A liver hormone released by fasting, sugar and protein restriction that signals through beta-klotho. Engineered analogues improved liver fibrosis in phase 2b MASH trials of 222 and 128 people; lifespan extension exists only in transgenic mice.
FGF21 is an endocrine fibroblast growth factor made mainly by the liver in response to fasting, ketogenic states, protein restriction, sugar intake and PPAR-alpha activation. Unlike the paracrine FGFs it lacks the heparin-binding domain that keeps them local, so it circulates, and it can act only on tissues that express its obligate co-receptor beta-klotho, principally fat, liver and parts of the brain.
Mechanism: Established in mice: fasting induces hepatic FGF21 through PPAR-alpha; FGF21 induces PGC-1alpha, drives fatty acid oxidation and ketogenesis, improves insulin sensitivity, suppresses growth hormone action, and causes bone loss. FGF21 signals through FGFR1c (and FGFR3c) only in the presence of beta-klotho, which is what restricts its action to fat, liver and specific brain regions.
Regulatory history: Not FDA-approved. Native FGF21 is not a drug. No FGF21 analogue (efruxifermin, pegozafermin, efimosfermin) had a Drugs@FDA record on 11 September 2026; efruxifermin and pegozafermin are in phase 3.
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for FGF21 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
FGF21 in other countries
Frequently asked questions
Is FGF21 legal in the United States?
No. FGF21 is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile. Note: Native FGF21 is not a product. The analogues efruxifermin, pegozafermin and efimosfermin are investigational.
Can I buy FGF21 in the United States?
No approved product exists to buy. In the United States FGF21 is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors. Note: Native FGF21 is not a product. The analogues efruxifermin, pegozafermin and efimosfermin are investigational.
Is FGF21 FDA approved?
No. FDA status: Not FDA-approved. Native FGF21 is not a drug. No FGF21 analogue (efruxifermin, pegozafermin, efimosfermin) had a Drugs@FDA record on 11 September 2026; efruxifermin and pegozafermin are in phase 3.. Current US classification: "Investigational, not approved". On the evidence, 4 human studies are cited on its profile.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for FGF21 live on its compound profile.
FGF21 profileThis page is general information about the regulatory status of FGF21 in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.